Rheumatology

Your Article Summary

See Latest Articles

Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: The JPOS study
Osteoporosis International, 06/08/09

Tamaki J et al. – Study concludes that the peroxisome proliferator-activated receptors gamma (PPARγ) polymorphism C161T is associated with low peak bone mass.

• Study examines the impact of PPARγ C161T polymorphism on bone mineral density (BMD) and its change
• A baseline survey in 1996 and a 10-yr f/u survey
• 1,217 participants were analyzed cross-sectionally, while longitudinal analysis was performed on 563 women

• Total hip and femoral neck BMDs were higher for CC genotype than for CT/TT genotypes among 664 premenopausal women
• Compared to the CC genotype, the odds ratio for osteopenia or osteoporosis at the femoral neck was 1.98 for premenopausal CT/TT genotypes
• Change of BMD at either skeletal site during the f/u period was not different for either menstrual status

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09

Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09

See All of Bone Metabolism